Cannabinoids reduce ErbB2-driven breast cancer progression through Akt inhibition.

Molecular Cancer
María M CaffarelCristina Sánchez

Abstract

ErbB2-positive breast cancer is characterized by highly aggressive phenotypes and reduced responsiveness to standard therapies. Although specific ErbB2-targeted therapies have been designed, only a small percentage of patients respond to these treatments and most of them eventually relapse. The existence of this population of particularly aggressive and non-responding or relapsing patients urges the search for novel therapies. The purpose of this study was to determine whether cannabinoids might constitute a new therapeutic tool for the treatment of ErbB2-positive breast tumors. We analyzed their antitumor potential in a well established and clinically relevant model of ErbB2-driven metastatic breast cancer: the MMTV-neu mouse. We also analyzed the expression of cannabinoid targets in a series of 87 human breast tumors. Our results show that both Delta9-tetrahydrocannabinol, the most abundant and potent cannabinoid in marijuana, and JWH-133, a non-psychotropic CB2 receptor-selective agonist, reduce tumor growth, tumor number, and the amount/severity of lung metastases in MMTV-neu mice. Histological analyses of the tumors revealed that cannabinoids inhibit cancer cell proliferation, induce cancer cell apoptosis, and impair tumor...Continue Reading

References

Nov 15, 1992·Proceedings of the National Academy of Sciences of the United States of America·C T GuyW J Muller
Jul 8, 1998·Proceedings of the National Academy of Sciences of the United States of America·L De PetrocellisV Di Marzo
Jun 22, 2000·International Journal of Cancer. Journal International Du Cancer·P NanniP L Lollini
Aug 3, 2002·Nature Reviews. Cancer·Ann F ChambersIan C MacDonald
Oct 23, 2003·Nature Reviews. Cancer·Manuel Guzmán
May 3, 2005·Nature Reviews. Cancer·Nancy E Hynes, Heidi A Lane
Jul 29, 2005·Nature·Andy J MinnJoan Massagué
Oct 15, 2005·Current Opinion in Oncology·Julie DecockTanja Cufer
May 27, 2006·The Journal of Pharmacology and Experimental Therapeutics·Alessia LigrestiVincenzo Di Marzo
Dec 29, 2006·Journal of Cellular Physiology·Simona PisantiMaurizio Bifulco
Apr 21, 2007·Nature Reviews. Cancer·Josie Ursini-SiegelWilliam J Muller
Jul 3, 2007·Cell·Brendan D Manning, Lewis C Cantley
Aug 10, 2007·Nature Reviews. Cancer·Kristopher K Frese, David A Tuveson
Sep 8, 2007·Journal of Molecular Medicine : Official Organ of the Gesellschaft Deutscher Naturforscher Und Ärzte·Angelo A IzzoUNKNOWN Endocannabinoid Research Group
Sep 14, 2007·Nature Reviews. Cancer·Carlos López-Otín, Lynn M Matrisian
Jan 18, 2008·Cancer Research·Sami SarfarazHasan Mukhtar
May 1, 2008·Nature Reviews. Drug Discovery·Vincenzo Di Marzo
Aug 5, 2008·Cancer Research·Dingzhi WangRaymond N DuBois
Nov 18, 2008·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Serena Di Cosimo, José Baselga
Nov 22, 2008·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Windy Dean-Colomb, Francisco J Esteva
Feb 20, 2009·British Journal of Pharmacology·Roger G Pertwee
Mar 26, 2009·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Rachael NatrajanJorge S Reis-Filho
Jun 19, 2009·Nature Reviews. Cancer·José Baselga, Sandra M Swain
Nov 6, 2009·Molecular Cancer Therapeutics·Zahida QamriRamesh K Ganju

❮ Previous
Next ❯

Citations

Sep 12, 2012·Journal of Molecular Medicine : Official Organ of the Gesellschaft Deutscher Naturforscher Und Ärzte·Julia KarglRudolf Schicho
Nov 1, 2011·Cancer Metastasis Reviews·Daniel J Hermanson, Lawrence J Marnett
Apr 23, 2013·Trends in Pharmacological Sciences·Simona PisantiMaurizio Bifulco
Dec 19, 2013·PloS One·Alexander H BenzFaramarz Dehghani
Dec 27, 2013·International Journal of Endocrinology·Thangesweran AyakannuJustin C Konje
Jan 20, 2011·Expert Opinion on Therapeutic Targets·Anna Maria MalfitanoMaurizio Bifulco
Feb 9, 2016·European Journal of Pharmacology·Farideh A JavidAlessia Ligresti
Jan 15, 2016·Life Sciences·Marjan NikanAzadeh Manayi
Feb 16, 2016·International Journal of Molecular Sciences·Irmgard Tegeder
Oct 30, 2012·Progress in Lipid Research·Iain BrownKlaus W J Wahle
Oct 25, 2011·Critical Reviews in Oncology/hematology·Daniel W BowlesAntonio Jimeno
Mar 18, 2011·British Journal of Pharmacology·Josée Guindon, Andrea G Hohmann
May 19, 2012·British Journal of Pharmacology·Luciano De PetrocellisVincenzo Di Marzo
Aug 21, 2012·Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research·Alysia N Lozano-OndouaTodd W Vanderah
May 14, 2014·The Journal of Pharmacy and Pharmacology·Natasha BeukesCarminita L Frost
Jun 15, 2015·Progress in Neuro-psychopharmacology & Biological Psychiatry·Guillermo VelascoMar Lorente
Jul 11, 2012·Cancer Treatment Reviews·María M CaffarelCristina Sánchez
Jan 12, 2013·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Helena FohlinOlle Stål
Apr 29, 2015·Journal of Neuroimmune Pharmacology : the Official Journal of the Society on NeuroImmune Pharmacology·Sean D McAllisterPierre-Yves Desprez
May 11, 2015·Human Reproduction Update·Thangesweran AyakannuJustin C Konje
Apr 12, 2014·American Journal of Obstetrics and Gynecology·Enrico Michelino MessalliRaffaele Rossiello
Apr 10, 2015·Journal of the National Cancer Institute·Eduardo Pérez-GómezCristina Sánchez
Mar 2, 2013·Oncology Nursing Forum·Susan Weiss Behrend
Apr 14, 2016·Expert Opinion on Therapeutic Targets·Robert Ramer, Burkhard Hinz
Nov 2, 2013·Journal of Natural Products·Katina S S DossouRuin Moaddel
Oct 21, 2016·Expert Opinion on Investigational Drugs·A I Fraguas-SánchezA I Torres-Suárez
Oct 25, 2016·Frontiers in Pharmacology·Daniel A LadinRukiyah Van Dross
Mar 22, 2012·Pharmacology·Christopher M Henstridge
Mar 7, 2017·Canadian Journal of Physiology and Pharmacology·Yan Lu, Hope D Anderson
Apr 18, 2018·British Journal of Pharmacology·Ana Isabel Fraguas-SánchezAna Isabel Torres-Suárez
Jul 19, 2018·British Journal of Pharmacology·Burkhard Hinz, Robert Ramer
Oct 31, 2018·Drugs·Ana Isabel Fraguas-Sánchez, Ana Isabel Torres-Suárez
May 5, 2012·Nature Reviews. Cancer·Guillermo VelascoManuel Guzmán
Jan 30, 2020·International Journal of Molecular Sciences·Laura PietrovitoPaola Chiarugi
Feb 29, 2020·Cancers·Luka DobovišekNataša Debeljak
Aug 15, 2014·Oncotarget·Bandana ChakravartiRamesh K Ganju
Apr 17, 2019·International Journal of Molecular Sciences·Terézia KiskováTheresia Thalhammer

❮ Previous
Next ❯

Methods Mentioned

BETA
PCR
PMA
xenografts
xenograft
X-ray
transfections
PCRs

Software Mentioned

SPSS
HercepTest
Metamorph Premier Offline
Quantity One

Related Concepts

Related Feeds

Breast Invasive Carcinoma

Invasive breast cancers indicate a spread into breast tissues and lymph nodes. Here are the latest discoveries pertaining to breast invasive carcinomas.

Breast Tumorigenesis

Breast tumorigenesis involves the production or formation of tumor(s) in breast tissue. Discover the latest research on breast tumorigenesis here.

Apoptosis in Cancer

Apoptosis is an important mechanism in cancer. By evading apoptosis, tumors can continue to grow without regulation and metastasize systemically. Many therapies are evaluating the use of pro-apoptotic activation to eliminate cancer growth. Here is the latest research on apoptosis in cancer.

AKT Pathway

This feed focuses on the AKT serine/threonine kinase, which is an important signaling pathway involved in processes such as glucose metabolism and cell survival.

Breast Invasive Carcinoma (Keystone)

Invasive breast cancers indicate a spread into breast tissues and lymph nodes. Here are the latest discoveries pertaining to breast invasive carcinomas.

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis

Carcinoma, Ductal

Ductal carcinoma is a malignant neoplasm involving the ductal systems of any of a number of organs, such as the mammary glands, pancreas, prostate or lacrimal gland. Discover the latest research on ductal carcinoma here.

Angiogenesis Inhibitors to Treat Cancer

Cancer treatments including angiogenesis inhibitors prevent tumor cells from receiving nutrients and oxygen. Here is the latest research on angiogenesis inhibitors for the treatment of cancer.